ArticleHemaSphere2025

Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma.

Núria Martínez-Cibrián et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.